ReviewFrontiers in oncology2025
NF-κB signaling pathway in osteosarcoma: from signaling networks to targeted therapy.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anti-myeloma mechanisms of the selective NF-κB inhibitor QNZ.Molecular therapy. Oncology · 2026Article
- Identification of a metastasis-associated prognostic gene signature in osteosarcoma through integrated bioinformatics and functional analysis.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is the most common primary malignant bone tumor that frequently occurs in children and adolescents. Although neoadjuvant chemotherapy has shown efficacy for OS, the long-term survival rate of OS patients remains low, highlighting the necessity of seeking more effective treatment methods. In cancer cells, abnormal activation of signaling pathways can widely affect cell activity from growth and proliferation to apoptosis, invasion and metastasis. As a highly complex and unique signal transduction pathway, the NF-κB pathway is involved in various physiological and pathological processes. In the field of oncology, the abnormal activation of the NF-κB pathway is closely related to the occurrence, development, metastasis and drug resistance of tumors, and is regarded as an important potential target for tumor treatment. Studies have confirmed that the NF-κB signaling pathway is an important driver of osteosarcoma. Abnormal activation of this pathway can promote the proliferation of osteosarcoma cells, inhibit apoptosis, enhance migration and invasion abilities, and immune escape processes. While inhibition of NF-κB pathway can effectively inhibit or reverse the above pathological processes. In this review, we summarized the role and mechanism of the NF-κB pathway in OS, discussed the therapeutic significance of targeting this pathway for OS, as well as the current insufficient research and problems to be solved regarding this pathway in OS. This review is helpful for us to understand the role of NF-κB on OS, and provides a theoretical basis for targeting the NF-κB pathway as a therapeutic target for OS and developing new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.